These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9581056)

  • 1. Pharmacokinetic-pharmacodynamic model for educational simulations.
    van Meurs WL; Nikkelen E; Good ML
    IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
    Zhang L; Beal SL; Sheinerz LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
    Vrijens B; Goetghebeur E
    Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
    Lees P; Giraudel J; Landoni MF; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the pharmacodynamic parameters in a model for neuromuscular block.
    Nigrovic V; Anton A; Bengez R
    Med Sci Monit; 2004 Dec; 10(12):BR468-76. PubMed ID: 15567978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interdependency of pharmacokinetic parameters: a chicken-and-egg problem? Not!
    Mehvar R
    J Pharm Pharm Sci; 2006; 9(1):113-8. PubMed ID: 16849012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic models for categorical toxicity data.
    Diack C; Bois FY
    Regul Toxicol Pharmacol; 2005 Feb; 41(1):55-65. PubMed ID: 15649827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model.
    Odeberg JM; Callréus T; Lundin S; Roth EB; Höglund P
    J Pharm Pharmacol; 2004 Nov; 56(11):1389-98. PubMed ID: 15525445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.